Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04959903 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
A Phase 1 study of Hematological Malignancies, sponsored by Smart Immune SAS.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT04959903 is a Phase 1 study of Hematological Malignancies that is actively recruiting participants, run by Smart Immune SAS. The registered enrollment target is 36 participants, below the 774-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04959903, a Phase 1 study of Hematological Malignancies, is actively recruiting participants, sponsored by Smart Immune SAS.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients with hematological malignancies.
Conditions Studied
Interventions
- BIOLOGICAL Allogeneic T cell progenitors, cultured ex-vivo
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center (MSKCC) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-03-31 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04959903
The ClinicalTrials.gov registry entry for NCT04959903 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 774-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (95% lower). The listed sponsor is Smart Immune SAS, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematological Malignancies appearing as the primary indexed condition, and to 1 intervention - of which Allogeneic T cell progenitors, cultured ex-vivo is the first listed.
NCT04959903 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04959903 about?
NCT04959903 is a clinical study titled "Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT". The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients with hematological malig...
What is the current status of trial NCT04959903?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-03-31. Estimated completion is 2027-05.
What conditions does trial NCT04959903 study?
This clinical trial studies the following conditions: Hematological Malignancies.
What interventions are being tested in trial NCT04959903?
The interventions under investigation include: Allogeneic T cell progenitors, cultured ex-vivo (BIOLOGICAL).
Who is sponsoring clinical trial NCT04959903?
This trial is sponsored by Smart Immune SAS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04959903 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematological Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
RECRUITING · Phase 1
-
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Durvalumab and Tremelimumab for Pediatric Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Study of AZD9829 in CD123+ Hematological Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.